Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc.

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Buy rating on Sera Prognostics. The company’s shares closed yesterday at ...

Market Cap	$139.69M	P/E Ratio	N/A
52W High	$4.09	52W Low	$1.37
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	24.8%	52W Position	26.5%
Overall Score	55	Value Score	60
Quality Score	44	Technical Score	63

EPS Current Est	$-0.66	EPS Next Est	$-0.68
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SERA	$2.09	0.00%	20.02K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SERA	$2.09	0%	20.02K
3
4
5
6

SERA

SERA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Sera Prognostics Inc. Data in Excel

Get Sera Prognostics Inc. Data in Excel